MEDFORD, N.Y., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced completion of the ...
A Hauppauge manufacturer of HIV tests has won a $2.7 million judgment against a former distributor in the United Kingdom. Chembio Diagnostics Inc. said this week that an arbitration tribunal found its ...
HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission ...
HATFIELD, Pa.--(BUSINESS WIRE)--Genisphere LLC has licensed its 3DNA® Signal Amplification technology to Chembio Diagnostics, Inc., a leader in point-of-care ("POC") diagnostic tests for infectious ...
Chembio Diagnostics, Inc. (OTCBB: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, and is the only New York-based manufacturer of rapid HIV/AIDS testing ...
Thinly traded nano cap Chembio Diagnostics (CEMI-13.1%) is down on modestly higher volume, only 148K shares, on the heels of an update on its U.S. marketing application for its DPP HIV-Syphilis Assay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results